Yaoshibang is a technology company.
Yaoshibang has raised $196.0M across 2 funding rounds.
Yaoshibang has raised $196.0M in total across 2 funding rounds.
Yaoshibang has raised $196.0M in total across 2 funding rounds.
Yaoshibang's investors include DCM.
Yaoshibang (药师帮), also known as Ysbang (9885.HK), is China's leading B2B pharmaceutical marketing and trading platform, connecting pharmaceutical factories, companies, pharmacies, and shop assistants via mobile internet.[1][2][3] Developed by Guangzhou Speedway Information Technology and founded in 2015, it serves the out-of-hospital pharmaceutical sector by enabling direct medicine ordering and delivery to patients, while providing comprehensive digital services like supply chain management.[1][2][3][5] The platform went public on the Hong Kong Stock Exchange in June 2023, raising $497.19M total funding with a current market cap of 5.02B and stock price of 7.38, demonstrating strong growth momentum through expansions like the $145M acquisition of Yikuai Pharmaceutical in October 2024.[2]
Yaoshibang emerged in 2015 from Guangzhou Speedway Information Technology in Guangzhou, China, addressing inefficiencies in the fragmented out-of-hospital pharmaceutical supply chain.[1][2] The platform quickly gained traction as a mobile-first B2B solution, evolving from a trading app to the largest digital service hub for pharmacies and related businesses outside hospitals.[3] Key milestones include securing $270M in funding for supply chain scaling and achieving IPO status in June 2023, followed by strategic moves like the 2024 Yikuai acquisition to bolster procurement and customer synergies.[2][4]
Yaoshibang rides the wave of China's digital health transformation, digitizing the massive out-of-hospital pharma market amid rising mobile penetration and e-commerce in healthcare.[2][3] Timing aligns with post-pandemic demand for efficient supply chains and direct-to-patient delivery, fueled by regulatory support for health tech and offline-to-online shifts in pharmacies.[5] Market forces like supply chain fragmentation and competition from traditional distributors favor its mobile B2B model, influencing the ecosystem by consolidating smaller players (e.g., Yikuai buyout) and setting standards for pharma tech scalability.[2]
Yaoshibang is poised for accelerated dominance through M&A and IPO-fueled expansion, targeting deeper integration in China's $100B+ out-of-hospital pharma sector. Trends like AI-driven supply optimization and regulatory tailwinds for digital health will shape its path, potentially evolving it into a full-stack pharma tech giant with global ambitions. As the go-to B2B platform bridging factories to patients, its momentum positions it to redefine accessible medicine distribution.[2][3]
Yaoshibang has raised $196.0M across 2 funding rounds. Most recently, it raised $130.0M Series D in December 2018.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2018 | $130.0M Series D | DCM | |
| Jun 1, 2018 | $66.0M Series C | DCM |